Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

801.15
Delayed Data
As of Nov 28
 +3.07 / +0.38%
Today’s Change
668.00
Today|||52-Week Range
853.97
+11.04%
Year-to-Date
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
Nov 27 / Zacks.com - Paid Partner Content
HRMY vs. REGN: Which Stock Is the Better Value Option?
Nov 21 / Zacks.com - Paid Partner Content
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
Nov 24 / Zacks.com - Paid Partner Content
Should You Invest in the iShares Biotechnology ETF (IBB)?
Nov 20 / Zacks.com - Paid Partner Content
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
Nov 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close798.08
Today’s open795.96
Day’s range792.43 - 801.61
Volume18,223
Average volume (3 months)462,331
Market cap$87.0B
Data as of 3:59pm ET, 11/28/2023

Growth & Valuation

Earnings growth (last year)-46.98%
Earnings growth (this year)-9.37%
Earnings growth (next 5 years)+2.38%
Revenue growth (last year)-24.26%
P/E ratio22.9
Price/Sales6.73
Price/Book3.86

Competitors

 Today’s
change
Today’s
% change
VRTXVertex Pharmaceutica...-3.25-0.93%
ZTSZoetis Inc-1.81-1.01%
----
BMYBristol-Myers Squibb-0.10-0.20%
Data as of 4:00pm ET, 11/28/2023

Financials

Next reporting dateFebruary 8, 2024
EPS forecast (this quarter)$10.21
Annual revenue (last year)$12.2B
Annual profit (last year)$4.3B
Net profit margin35.64%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
Tarrytown, New York

Forecasts